Clinical trials: Hematological Disease
Waldenstrom's Macroglobulinemia, Lymphoplasmacytic Lymphoma
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
The purpose of this study is to evaluate how tumors in patients with Waldenstrom's macroglobulinemia respond to treatment with bortezomib (Velcade) and to see what effects (good and bad) it has on the cancer.
- Trial name
- NCT00142129
- Testing
- Bortezomib (Velcade)
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma in Relapse
A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
Primary objective: To determine the incidence of infusion related reactions (IRR's) in the first 6 months of daratumumab administration.
- Trial name
- NCT03697629
- Testing
- Daratumumab
- Where
- 6 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Canadian Myeloma Research Group
Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
This phase I/II trial studies the side effects and best dose of vorinostat and azacitidine and to see how well they work in treating patients with myelodysplastic syndromes or acute myeloid leukemia.
- Conditions
- Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
- Trial name
- NCT00392353
- Testing
- Azacitidine, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 7 sites in United States
- Volunteers
- 135 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myelogenous Leukemia
Lenalidomide Plus Chemotherapy for AML
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational combination of drugs.
- Trial name
- NCT01681537
- Testing
- Lenalidomide, Mitoxantrone, Etoposide
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
Hemoglobin, Stem Cell Transplant
Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease
Background: Some treatments for cancer or other diseases can lead to infertility in women. These treatments include chemotherapy, some stem cell transplants, and pelvic radiotherapy. They are called gonadotoxic therapies.
- Conditions
- Hemoglobin, Stem Cell Transplant, Aplastic Anemia
- Trial name
- NCT02225145
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Hematologic Cancer
Virtual Reality Intervention to Improve Comfort in Hospitalized Hematology Patients
The objective of this clinical trial is to determine whether virtual reality (VR) devices can improve comfort and quality of life in hospitalized adult patients with hematological malignancies who require at least 15 consecutive…
- Trial name
- NCT07894601
- Testing
- Immersive virtual reality experience
- Where
- 2 sites in Spain
- Volunteers
- 145 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Hematologic Neoplasms, Solid Tumor Metastatic Cancer Advanced Cancer
Role of Fibrinolytic Activity in Neoplastic Pathologies Complicated by Coagulopathy
The aim of this research is to measure fibrinolytic activity in neoplastic pathologies in order to provide preliminary data on which to base a future, larger-scale study to determine predictive markers of complication in order to…
- Conditions
- Hematologic Neoplasms, Solid Tumor Metastatic Cancer Advanced Cancer, Disseminated Intravascular Coagulation
- Trial name
- NEO-COAG (NCT07234630)
- Testing
- An additional volume of blood will be drawn as part of routine follow-up care
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Strasbourg, France
Chronic Myeloid Leukemia
Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
The goal of this clinical research study is to find out if treatment with a combination of dasatinib plus ropeginterferon can help to control CML-CP. The safety of this combination will also be studied.
- Trial name
- NCT07269470
- Testing
- Dasatinib, Ropeginterferon alfa-2b (P1101)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Sickle Cell Disease
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512.
- Trial name
- NCT06546670
- Testing
- ITU512
- Where
- 14 sites in United States, Brazil and 1 more
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)
This study aims to assess the efficacy of peginterferon α-2b, compared to a control arm not receiving any maintenance treatment, in adult subjects with multiple myeloma who have responded to a prior induction therapy.
- Trial name
- NCT00732641
- Testing
- Peginterferon
- Volunteers
- 244 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
The purpose of this study is to determine the tolerated dose of pomalidomide and also to evaluate the pharmacokinetics, safety and efficacy of pomalidomide in patients with refractory or relapsed and refractory multiple myeloma.
- Trial name
- NCT01568294
- Testing
- pomalidomide
- Where
- 8 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Celgene
Hemophilia A, Hemophilia A, Congenital
Searching Patterns In the Robustness of Immunological FVIII Tolerance
Children with hemophilia A lack clotting factor VIII (FVIII) due to a genetic mutation. It is well known that administration of FVIII concentrate leads to immunological tolerance for the FVIII protein in the majority of children.
- Trial name
- SPIRIT (NCT07539402)
- Where
- Netherlands
- Volunteers
- 500 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Acute Myeloid Leukemia
Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)
A study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside (LDAC) in patients with acute myeloid leukaemia (AML).
- Trial name
- NCT00926731
- Testing
- AZD1152, LDAC (low dose cytosine arabinoside)
- Where
- 4 sites in United States, France
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This clinical trial is looking at a drug called alectinib. Alectinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770037)
- Testing
- Alectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Chronic Myeloproliferative Disorders, Leukemia
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of 506U78 in treating patients who have hematologic cancer…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004239
- Testing
- Compound 506U78
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Acute Myeloid Leukemia
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
The purpose of this study is to evaluate the dose-limiting toxicities (DLT) and define the maximum tolerated dose (MTD) and the recommended phase II study dose of gilteritinib when combined with mitoxantrone, cladribine…
- Trial name
- NCT05330377
- Testing
- Gilteritinib 40 MG Oral Tablet, Cladribine, Cytarabine
- Where
- United States
- Sponsor
- Ayman H Qasrawi
Acute Myeloid Leukemia (AML)
Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France
The purpose of this study is to collect and evaluate real-world data to describe the outcomes, patient characteristics, safety profile and treatment patterns of oral azacitidine prescribed as maintenance treatment after frontline…
- Trial name
- RELION (NCT06565975)
- Testing
- Oral azacitidine
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Bristol-Myers Squibb
Neutropenia, Thrombocytopenia
Effects of Levetiracetam Monotherapy on Various Hematological Parameters in Adult Patients Suffering of Epilepsy
Low therapeutic index of established antiepileptic drugs (AEDs) coupled with better understanding of the pathophysiology of seizure has encouraged the development of several novel AEDs.
- Conditions
- Neutropenia, Thrombocytopenia, Aplastic Anemia, Anemia
- Trial name
- NCT06491303
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Assiut University
Multiple Myeloma
Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
The primary objectives are: Phase 1b: To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of oprozomib given orally, once daily, on 2 different schedules.
- Trial name
- NCT01832727
- Testing
- Oprozomib, Dexamethasone
- Where
- 13 sites in United States, France
- Volunteers
- 65 people
- Sponsor
- Amgen
Congenital Heart Disease, Pediatric ALL
HIIT in Youth With Congenital Heart Disease (MedBIKE)
Congenital heart disease (CHD), the most common birth defect, is present in nearly 1% of the population. CHD patients are associated with intense resource utilization and premature death in adulthood.
- Trial name
- NCT04575883
- Testing
- MedBIKE HIIT
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- University of Alberta
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.